Clinical trials: Neuroendocrine Neoplasm
Lung Neoplasm, Melanoma
Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies
Single-center, randomized clinical trial (RCT) with low intervention level (Telenursing), for the monitoring of patients affected by lung cancer and melanoma who are candidates for first prescription with Targeted Therapies.
- Trial name
- Telenursing (NCT06254196)
- Testing
- Telenursing interventions for monitoring Supportive Care Needs
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Regina Elena Cancer Institute
Head and Neck Cancer
The Physiological Response to Routine Head and Neck Cancer Surgery
The main objective of this pilot study is to observe and document the range of changes in the blood concentrations of certain hormones, inflammatory chemicals and immune chemicals in response to the stimulus of Head and Neck…
- Trial name
- NCT01032096
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Uveal Melanoma, Metastatic
Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp
The goal of this clinical trial is to learn if a low dose of dexamethasone can prevent cytokine release syndrome in participants treated with tebentafusp for advanced uveal melanoma.
- Trial name
- LODEXA (NCT07803562)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Diego
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Background: Lung cancers with epidermal growth factor receptor (EGFR) mutations may develop resistance to therapies targeting this protein by evolving/being transformed into small cell or neuroendocrine cancers.
- Trial name
- NCT04538378
- Testing
- Olaparib, Durvalumab, EKG
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
The purpose of the study is to evaluate, in standard practice, the change in information received and perceived by the patient, extension of the disease and its treatment.
- Trial name
- OPERA (NCT03562091)
- Testing
- Data collection
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Ipsen
Melanoma Stage III, Melanoma Stage IV
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for…
- Trial name
- INTACT/MeRCI (NCT06284590)
- Testing
- L19IL2, L19TNF, L19IL2/L19TNF
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 162 people
- Sponsor
- Philogen S.p.A.
Neuroendocrine Tumours (NET)
United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare…
- Trial name
- PREF-NET (NCT04649580)
- Where
- 5 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- Ipsen
Adjuvant, Stage III Malignant Melanoma
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood with distant metastasis free survival (DMFI) as a primary…
- Conditions
- Adjuvant, Stage III Malignant Melanoma, Interferon Alpha, Therapy
- Trial name
- NCT00226408
- Testing
- Interferon-alpha-2b
- Where
- 13 sites in Germany
- Volunteers
- 600 people
- Sponsor
- Dermatologic Cooperative Oncology Group
Neuroendocrine Tumors
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging associated with pathological…
- Trial name
- NCT03288597
- Testing
- 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET, 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Peking University
Melanoma (Skin)
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and…
- Trial name
- NCT00006113
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Southern California
Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.
- Trial name
- NCT00577382
- Testing
- Sunitinib
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Uveal Melanoma
Psychoeducation for Uveal Melanoma
This clinical trial evaluates a video-based psychoeducational intervention for patients with uveal melanoma. Uveal melanoma (UM) is a rare intraocular cancer.
- Trial name
- NCT06075589
- Testing
- Education for Intervention, Best Practice
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Melanoma
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Patients with BRAF V600 mutant advanced melanoma benefit from treatment with a BRAF-inhibitor (e.g. dabrafenib, vemurafenib) and from combination of a BRAF- and MEK-inhibitor (e.g. dabrafenib and trametinib).
- Trial name
- NCT02296996
- Testing
- Dabrafenib + Trametinib
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- Universitair Ziekenhuis Brussel
Melanoma, Skin Cancer
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00002882
- Testing
- Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IIIB Melanoma, Stage IIIC Melanoma
Dinaciclib in Treating Patients With Stage III-IV Melanoma
This is a phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with advanced melanoma.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01026324
- Testing
- dinaciclib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastroenteropancreatic Neuroendocrine Tumor
68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are a heterogeneous group of neoplasms that arise from the endocrine cells of the gastroenteropancreatic tract.
- Trial name
- NCT06155318
- Testing
- 68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS San Raffaele
Melanoma
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
The study plans to treat patients with pembrolizumab and thus blocking the PD-1/PD-L1 axis would render tumor-infiltrating lymphocytes (TILs) in the tumor parenchyma more functional as a consequence of BRAF inhibition, such that…
- Trial name
- NCT02818023
- Testing
- Pembrolizumab, Vemurafenib, Cobimetinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yana Najjar
Thyroid Diseases, Thyroid Neoplasms
Thyroid Health Outcomes Registry for Surgery
THORS is a single-center ambidirectional observational cohort study conducted at Moscow Multidisciplinary Clinical Center "Kommunarka".
- Conditions
- Thyroid Diseases, Thyroid Neoplasms, Thyroid Cancer, Thyroid Nodules
- Trial name
- THORS (NCT07812779)
- Volunteers
- 3,000 people
- Sponsor
- Pirogov Russian National Research Medical University